NextPoint Therapeutics, Inc.
5 additional officers and directors, 1 additional investor
Every relationship, signal and contact on this record, with the source on each.
Includes 3 days of DFX Intelligence. Then $199/month unless canceled.
What matters now
- $33.7Msold on Form D
Filed a Form D on 22 Jul 2026: $33.7M sold on Form D. A Form D is an offering filing; it names no investors, stage or valuation.
A company that just raised has fresh capital, a new board and new vendors to choose.
- 2 investorsnamed
2 investors on record.
The investors already on the cap table shape who leads the next round.
- 8 directorsboard
8 directors on record from Form D filings and board-seat attributions.
The board is who decides on the next round and on a sale.
Facts
- Year of incorporation
- unknown
- Revenue range (Form D)
- Decline to Disclosesec.gov
- Rounds on record
- 2
- Disclosed raised
- unknownsum of rounds with a disclosed amount only
- Named investors
- 2
Financing history
- Jul 22, 2026Form D equity offering · $33.7M (form d sold) · 15 investorsFact Form D · “NextPoint Therapeutics, Inc. filed Form D: $33,728,772 sold of $48,729,165, Biotechnology”
- Jan 31, 2024Form D equity offering · $42.5M (form d sold) · 15 investorsCatalio Capital Management, LP via R. Jacob VogelsteinFact Form D · “NextPoint Therapeutics, Inc. filed Form D: $42,479,388 sold of $42,479,388, Biotechnology”
Investors on record
- Catalio Capital Management, LP portfolio listing Fact cataliocapital.com
- Catalio Capital Management, LP board only, R. Jacob Vogelstein (strongly supported) Inference sec.gov
- MPM Bioimpact board only, Detlev Biniszkiewicz (strongly supported) Inference sec.gov
Ownership and outcomes
How these are wordedA company a buyout or growth firm lists on its own site is “listed in the portfolio of”, never “acquired by”. A date prints only when a deal record gives one; otherwise the row says when DFX first saw it.Listed on 1 firm portfolio page; none states an outcome (acquired, public, exited or active). DFX does not assume the company is active.
Evidence: 1 listingeach firm's own card, as read
- Status not stated on Catalio Capital Management, LP · the firm's card prints no outcome · read Sep 30, 2026 cataliocapital.com“NextPoint Therapeutics”
Credit relationships
How a loan is matchedA BDC reports its loans by borrower name. A position shows here only when the match passed a precision gate (a hand-labelled sample was 29 of 30 correct); the tier and confidence are printed on each row. Amounts are the lender’s reported position, never a round.People
- Ivan Cheung Executive Officer/Director sec.gov
- Jeffrey Lacey Executive Officer sec.gov
- Paul Conrad Executive Officer sec.gov
- R. Jacob Vogelstein Director Inference
- Brian Shuster Director Fact
Show all 6 officers and directors
- Ivan Cheung Executive Officer/Director sec.gov
- Jeffrey Lacey Executive Officer sec.gov
- Paul Conrad Executive Officer sec.gov
- R. Jacob Vogelstein Director Inference
- Brian Shuster Director Fact
- Axel Hoos Director Fact
Timeline
Evidence
Every observation on this company
- Entity type: Corporation Jul 30, 2026 Fact Form D
- Entity type: Corporation Feb 14, 2024 Fact Form D
- Form D industry group: Biotechnology Jul 30, 2026 Fact Form D
- Form D industry group: Biotechnology Feb 14, 2024 Fact Form D
- Amendment: false Jul 30, 2026 Fact Form D
- Amendment: false Feb 14, 2024 Fact Form D
- Revenue range (Form D): Decline to Disclose Jul 30, 2026 Fact Form D
- Revenue range (Form D): Decline to Disclose Feb 14, 2024 Fact Form D
- Incorporated: overFiveYears Jul 30, 2026 Fact Form D
- Incorporated: overFiveYears Feb 14, 2024 Fact Form D
- Jurisdiction: Delaware Jul 30, 2026 Fact Form D
- Jurisdiction: Delaware Feb 14, 2024 Fact Form D
- Amount sold (Form D): $33.7M Jul 30, 2026 Fact Form D
- Amount sold (Form D): $42.5M Feb 14, 2024 Fact Form D
- Offering amount (Form D): $48.7M Jul 30, 2026 Fact Form D
- Offering amount (Form D): $42.5M Feb 14, 2024 Fact Form D
- Exemptions: 06b Jul 30, 2026 Fact Form D
- Exemptions: 06b Feb 14, 2024 Fact Form D
- First sale: 2026-07-22 Jul 30, 2026 Fact Form D
- First sale: 2024-01-31 Feb 14, 2024 Fact Form D
- Investors (Form D): 15 Jul 30, 2026 Fact Form D
- Investors (Form D): 15 Feb 14, 2024 Fact Form D
- Minimum investment (Form D): 0 Jul 30, 2026 Fact Form D
- Minimum investment (Form D): 0 Feb 14, 2024 Fact Form D
- Securities offered: Equity, option Jul 30, 2026 Fact Form D
- Securities offered: equity Feb 14, 2024 Fact Form D
- Office address: Jul 30, 2026 Fact Form D
- Office address: Feb 14, 2024 Fact Form D
- Listed on portfolio page: Sep 30, 2026 Fact
- Listed on portfolio page: Sep 16, 2026 Fact
- Listed on portfolio page: Sep 15, 2026 Fact
Relationships across DFX
on 1 other DFX graph
NextPoint Therapeutics, Inc. is the same institution as 1 record in Private Equity.
The joined record opens with the product, beside every other relationship on this page.
Checking your plan…
Record history
- Form D filed2026-07-30source on record
- Form D filed2024-02-14source on record
The ledger records every merge, rename and reclassification this record went through and the dated filings observed on it, so the identity on this page can be traced to the records it was built from. The ledger's own sentences name other records, so they show with the names.